摘要
就^(131)I-CEA单克隆抗体在22例卵巢癌病人放射免疫显像中的血药动力学及人抗鼠抗体反应进行了观察。^(131)I-CEA单抗的血清T_1/2α=24.8小时,T_1/2β=40.5小时,循环血液中放射性主要存在于血浆蛋白中。在静脉给药后28小时内约有给予放射性总剂量的50％由尿排出。在接受单次静注标记抗体后2～3周病人体内即可产生人抗鼠抗体,在体内维持至少9个月以上。二次静注标记抗体后抗鼠抗体的产生影响了二次显像效果。
The pharmocokinetics and human anti-murine antibody response of 131I labelled anti-CEA monoclonal antibody have been examined in 22 ovarian cancer patients who were receiving labelled antibody in diagnostic immunoscintigraphy trial A bi-phasic dec- line of radiolabeled preparations was measured with α phase half-lives 24 .8 hours ana men with β phase half-lives40 .5 hours. Blood-borne radioactivity was associated predominantly with plasma rather than cellular elements . Urinary excretion of radioactivity was about 50% of injected dose in the first 28 hours. However, anti-murine antibody (HAMA) detected within two weeks of administration of radiolabelled antibody was present for at least 9 months, and has implications for the efficiency of repeated image studies.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1993年第6期492-495,共4页
Chinese Journal of Cancer
基金
山东省自然科学基金
关键词
癌胚抗原
药代动力学
卵巢肿瘤
Carcinoembryonic antigen(CEA) Antibody. Monoclonal Pharmocokinetics Ovarian neoplasms Human anti-murine antibody response
